Ikena Oncology Q4 2023 Earnings Report $1.47 0.00 (0.00%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Ikena Oncology EPS ResultsActual EPS-$0.41Consensus EPS -$0.41Beat/MissMet ExpectationsOne Year Ago EPSN/AIkena Oncology Revenue ResultsActual Revenue$0.66 millionExpected Revenue$2.39 millionBeat/MissMissed by -$1.73 millionYoY Revenue GrowthN/AIkena Oncology Announcement DetailsQuarterQ4 2023Date3/12/2024TimeN/AConference Call ResourcesIKNA Earnings History Ikena Oncology Earnings HeadlinesWilliam Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)December 29, 2024 | markets.businessinsider.comiKena Oncology, Inmagene enter definitive merger agreement, private placementDecember 24, 2024 | markets.businessinsider.comYour chance to get on the next “60-Second Trade”Even retirees are being forced back to work just to keep up. And if you're waiting for help from the Fed or government... Well, you might be waiting a very long time. But Roger Scott has uncovered something interesting... What if there was a way to fight back against inflation? A simple method you could use right from your phone...January 23, 2025 | WealthPress (Ad)Ikena Oncology Shares Rise After Merger Announcement With Inmagene BiopharmaceuticalsDecember 23, 2024 | marketwatch.comIkena Oncology, Inmagene Biopharmaceuticals to MergeDecember 23, 2024 | marketwatch.comIkena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementDecember 23, 2024 | globenewswire.comSee More Ikena Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email. Email Address About Ikena OncologyIkena Oncology (NASDAQ:IKNA) operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.View Ikena Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025)HCA Healthcare (1/24/2025)AT&T (1/27/2025)Starbucks (1/28/2025)PACCAR (1/28/2025)Intuitive Surgical (1/28/2025)General Motors (1/28/2025)RTX (1/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
